Olga Martelli

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

Marina Chiara Garassino, Olga Martelli, Massimo Broggini et al. · The Lancet Oncology · 2013 · 476 citations

Second-line Treatment, Oncology, Wild-type Egfr Tumours +9

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

Alessandro Russo, Marco Russano, Tindara Franchina et al. · Advances in Therapy · 2020 · 165 citations

Medicine, Immunology, Hematology +9

Short Hydration Regimen and Nephrotoxicity of Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatient Treatment in Lung Cancer and Mesothelioma

Marcello Tiseo, Olga Martelli, Andrea Mancuso et al. · Tumori Journal · 2007 · 85 citations

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

Francesco Passiglia, Federico Cappuzzo, Oscar Alabiso et al. · British Journal of Cancer · 2018 · 85 citations · Full text

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis

Marina Chiara Garassino, Valter Torri, G. Michetti et al. · Lung Cancer · 2010 · 61 citations

Oncology, Multi-institutional Retrospective Analysis, Cancer Management +7